^
Association details:
| Biomarker: | TPR-NTRK1 fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
Excerpt:
A TPR-NTRK1 fusion (Fig 1) was detected by NGS (Trailblaze Pharos Assay, Ignyta, San Diego, CA). He began receiving entrectinib on September 20, 2016. Immediately after initiating treatment, the patient experienced clinical benefit.
DOI:
10.1200/PO.18.00039
Trial ID:
Test:
